Covid-19 roundup: WHO rec­om­mends against 'high cost' remde­sivir, dis­ap­point­ing Gilead; EU deals with Pfiz­er/BioN­Tech, Cure­Vac top $10B — re­port

Vek­lury, or remde­sivir, may be the first Covid-19 treat­ment to earn full ap­proval at the FDA, af­ter it won a full-throat­ed en­dorse­ment from Pres­i­dent Trump. But the WHO is tak­ing the op­po­site view.

The UN agency said a pan­el tasked with de­vel­op­ing its guide­lines has rec­om­mend­ed against the use of remde­sivir, an an­tivi­ral Gilead orig­i­nal­ly de­vel­oped for Ebo­la, for Covid-19, cit­ing lim­it­ed da­ta sup­port­ing its ben­e­fits on one hand and “rel­a­tive­ly high cost and re­source im­pli­ca­tions as­so­ci­at­ed” with the in­tra­venous drug on the oth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER